Opisthorchis Viverrini

2

Review clinical trials related to Opisthorchis Viverrini. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini

This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.

Participants needed: 125
Trial details
Phase: Phase 2Age: 6-7Biological sex: AllType: InterventionalSponsor: Jennifer KeiserUpdated: Mar 20, 2026Locations: 1
Eligibility criteria

Aged 6 to 7 years (i.e., 72 to 95 months). [+4]

Presence or signs of major systemic illness, e.g. severe anaemia (haemoglobin le... [+7]

Status: Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia. Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Participants needed: 10,000
Trial details
Age: 2-75Biological sex: AllType: ObservationalSponsor: Institut Pasteur du CambodgeUpdated: Jan 22, 2026Locations: 1
Eligibility criteria

Residency in the village for more than 6 months; [+3]

Unable to understand or consent; [+3]